Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma

Zou Y, Yang Zou, Fa-Ying Liu, Faying Liu, Liu FY, Liu H, Huai Liu, Feng Wang, Wang F, Wei Li, Li W, Huang MZ, Mei-Zhen Huang, Meizhen Huang, Huang Y, Yan Huang, Yuan XQ, Xiao-Qun Yuan, Xiao-Yun Xu, Xiaoyun Xu, Xu XY, Huang OP, Ou-Ping Huang, Ouping Huang, Ming He
Mutation research · 2014 · vol. 761 , pp. 49–52 · doi:10.1016/j.mrfmmm.2014.01.003 · PMID:24472300 · W2007758859
Other OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the frequency of the POLE1 p.S297F mutation in Chinese patients diagnosed with ovarian endometrioid carcinoma.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The catalytic subunit of DNA polymerase epsilon (POLE1) functions primarily in nuclear DNA replication and repair. Recently, POLE1 mutations were detected frequently in colorectal and endometrial carcinomas while with lower frequency in several other types of cancer, and the p.P286R and p.V411L mutations were the potential mutation hotspots in human cancers. Nevertheless, the mutation frequency of POLE1 in ovarian cancer still remains largely unknown. Here, we screened a total of 251 Chinese samples with distinct subtypes of ovarian carcinoma for the presence of POLE1 hotspot mutations by direct sequencing. A heterozygous somatic POLE1 mutation, p.S297F (c.890C>T), but not p.P286R and p.V411L hotspot mutations observed in other cancer types, was identified in 3 out of 37 (8.1%) patients with ovarian endometrioid carcinoma; this mutation was evolutionarily highly conserved from Homo sapiens to Schizosaccharomyces. Of note, the POLE1 mutation coexisted with mutation in the ovarian cancer-associated PPP2R1A (protein phosphatase 2, regulatory subunit A, α) gene in a 46-year-old patient, who was also diagnosed with ectopic endometriosis in the benign ovary. In addition, a 45-year-old POLE1-mutated ovarian endometrioid carcinoma patient was also diagnosed with uterine leiomyoma while the remaining 52-year-old POLE1-mutated patient showed no additional distinctive clinical manifestation. In contrast to high frequency of POLE1 mutations in ovarian endometrioid carcinoma, no POLE1 mutations were identified in patients with other subtypes of ovarian carcinoma. Our results showed for the first time that the POLE1 p.S297F mutation, but not p.P286R and p.V411L hotspot mutations observed in other cancer types, was frequent in Chinese ovarian endometrioid carcinoma, but absent in other subtypes of ovarian carcinoma. These results implicated that POLE1 p.S297F mutation might be actively involved in the pathogenesis of ovarian endometrioid carcinoma, but might not be actively involved in other subtypes of ovarian carcinoma.

My notes (saved in your browser only)

MeSH descriptors

Asian People Carcinoma, Endometrioid DNA Polymerase II Endometrial Neoplasms Mutation Mutation Neoplasms, Glandular and Epithelial Ovarian Neoplasms Adolescent Adolescent Adult Adult Aged Aged Amino Acid Sequence Amino Acid Sequence Asian People Asian People Carcinoma, Endometrioid Carcinoma, Endometrioid

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (3)

References (21)

Cited by (3)

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:13:13.905685+00:00
unpaywall
last seen: 2026-10-11T06:28:45.473802+00:00
License: CC0 · commercial use OK